AML Clinical Trial
Official title:
Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3 Internal Tandem Duplication (ITD)
Patients with refractory or relapsed acute myeloid leukemia (AML) after two courses of standard chemotherapy regimens have very limited options. Further chemotherapy is associated with significant toxicity and is generally ineffective. About 10-30% patients with AML carry a gain-of-function mutation of a gene known as Flt3 in the leukemic cells, conferring them with abnormal cellular proliferation. Sorafenib is a multi-kinase inhibitor which was licensed in Hong Kong for the treatment of advanced hepatocellular and renal cell carcinoma. The drug has also been shown to be effective against Flt3 and AML but it has not been licensed for use in this condition.
AML is one of the most lethal cancers among young people in Hong Kong. Induction chemotherapy
is the mainstay of treatment, resulting in remission (i.e. clearance of leukemic cells) in
70% cases. Patients who fail induction chemotherapy or who relapse after initial remission
would need to receive further chemotherapy with a view to achieve a second remission. Those
who do so can be potentially cured by bone marrow transplantation (BMT). Those who fail are
left with very little options. As a result, only 30% patients can survive long-term.
AML is heterogeneous and 10-30% patients carry a gain-of-function mutation of a gene known as
fms-related tyrosine kinase-3 (Flt3) in the leukemic cells, which confers them with abnormal
cellular proliferation. These patients have inferior prognosis compared with those without
the mutation. With conventional chemotherapy, these leukemias often fail to remit, precluding
patients from receiving curative BMT. Sorafenib is a multi-kinase inhibitor which is FDA
approved for the treatment of metastatic hepatocellular and renal cell carcinomas. It is also
effective against Flt3 and has been shown to be very effective in inducing remission in
patients with AML carrying Flt3 mutation.
This proposal aims to treat relapsed or refractory AML patients carrying Flt3 mutation in the
following ways:
1. Patients who have persistent or refractory leukemia after at least two prior
chemotherapy regimens will receive sorafenib to induce a remission, hence bridging them
to BMT for curative treatment.
2. Patients who relapse after BMT will receive sorafenib to induce remission again in
preparation for second BMT.
3. Patients who are not candidates for BMT but have persistent or refractory leukemia after
at least two prior chemotherapy regimens will receive sorafenib to induce a remission,
followed by chemotherapy consolidation. Sorafenib induction will have significantly less
side-effects compared with induction by conventional chemotherapy.
Patients who are treated with sorafenib will be managed in the hospital and out-patient
clinics in the same way as patients undergoing induction by conventional chemotherapy. They
will have bone marrow examinations before and one month after receiving sorafenib treatment
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03118466 -
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 2 | |
Not yet recruiting |
NCT06313437 -
Revumenib in Combination With 7+3 + Midostaurin in AML
|
Phase 1 | |
Withdrawn |
NCT03444649 -
Epacadostat, Idarubicin and Cytarabine (EIC) in AML
|
Phase 1 | |
Withdrawn |
NCT02905994 -
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT02261779 -
Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible
|
Phase 1/Phase 2 | |
Completed |
NCT00246649 -
Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia
|
N/A | |
Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
Terminated |
NCT04079738 -
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
|
Phase 1/Phase 2 | |
Completed |
NCT03466320 -
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03138395 -
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
|
N/A | |
Terminated |
NCT01570465 -
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
|
||
Completed |
NCT04443751 -
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 1 | |
Terminated |
NCT03761069 -
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
|
Phase 1 | |
Completed |
NCT02631993 -
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia
|
N/A | |
Completed |
NCT02575963 -
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00780598 -
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
|
Phase 2 | |
Completed |
NCT00863148 -
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Completed |
NCT00761449 -
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
|
Phase 2 | |
Completed |
NCT00542971 -
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
|
Phase 1/Phase 2 | |
Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A |